Your browser is no longer supported

For the best possible experience using our website we recommend you upgrade to a newer version or another browser.

Your browser appears to have cookies disabled. For the best experience of this website, please enable cookies in your browser

We'll assume we have your consent to use cookies, for example so you won't need to log in each time you visit our site.
Learn more

COPD drug enters use in UK

  • Comment

The first in a new class of drug for treating chronic obstructive pulmonary disease has been launched in the UK.

Roflumilast (Daxas) is the first orally administered selective phosphodiesterase 4 (PDE4) inhibitor to be licensed for COPD.

It is indicated for maintenance treatment of severe COPD - FEV1 post-bronchodilator less than 50 per cent predicted - associated with chronic bronchitis in adult patients with a history of frequent exacerbations as an add on to bronchodilator treatment.

  • Comment

Have your say

You must sign in to make a comment

Please remember that the submission of any material is governed by our Terms and Conditions and by submitting material you confirm your agreement to these Terms and Conditions. Links may be included in your comments but HTML is not permitted.

Related Jobs